Promising Phase 3 Trial Of Tuberculosis Vaccine Is Running Ahead Of Schedule - Health Policy Watch A Phase 3 trial for the tuberculosis vaccine known as M72/AS01E is running a year ahead of schedule and has already recruited 90% of the 20,000 people it

A Phase 3 trial for the #tuberculosis vaccine known as M72/AS01E is running a year ahead of schedule and has already recruited 90% of the 20,000 people it needs.

✍️ @kerrycullinan.bsky.social
@gatesmri.bsky.social
@gatesfoundation.bsky.social

#TBDay2025 | #WorldTBDay2025